Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 9/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095133 | 0.91 | PTGES (0.50) | HRH3PTGESPTGS2 | |
| SCHEMBL3104207 | 0.80 | SOS1 (0.61) | SOS1GPR119PTGESPIK3CGHTR6 | |
| SCHEMBL3088134 | 0.76 | SOS1 (0.56) | SOS1GPR119PTGESPTGS2PIK3CG | |
| SCHEMBL24462170 | 0.75 | PTGES (0.49) | SOS1PTGESPTGS2PIK3CG | |
| SCHEMBL21154013 | 0.73 | NPC1 (0.50) | SOS1GPR119PTGESPTGS2PIK3CG | |
| SCHEMBL6869433 | 0.71 | HTR3A (0.67) | — | |
| SCHEMBL3114607 | 0.71 | PTGES (0.52) | PTGESPTGS2 | |
| SCHEMBL2861946 | 0.71 | DPP4 (0.78) | DPP4 | |
| SCHEMBL3101725 | 0.70 | HTR3E (0.55) | PTGESPTGS2HTR6 | |
| SCHEMBL24462046 | 0.70 | PIK3CG (0.43) | SOS1PTGESPTGS2PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465732-B2 | (2S,4S)-4-(piperazin-1-yl)pyrrolidine-2-methanone derivatives | PFIZER INC (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-20070099897-A1 | Therapeutic compounds | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| US-20060079498-A1 | Therapeutic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099897-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | SOS1 3821/4885HRH3 996/4885GPR119 8/4885 |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | SLC5A2, SLC5A1, REN | SOS1 3821/4885HRH3 996/4885GPR119 8/4885 |
| US-20060079498-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | SOS1 3821/4885HRH3 996/4885GPR119 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.